Erg Activators
Common Erg Activators include, but are not limited to Sorafenib CAS 284461-73-0, Bicalutamide CAS 90357-06-5, Trichostatin A CAS 58880-19-6, Dasatinib CAS 302962-49-8 and MDV3100 CAS 915087-33-1.
Erg Activators is a chemical class designed to target Erg proteins, a subset of the ETS family of transcription factors. These proteins play pivotal roles in gene regulation, affecting essential cellular processes such as proliferation, differentiation, and development. Erg Activators would interact with Erg proteins, influencing their DNA-binding affinity and subsequently altering their transcriptional activity. This interaction might result in the modulation of gene expression patterns controlled by Erg proteins, thereby affecting diverse cellular functions.
Erg proteins are known for their unique DNA-binding domains that enable them to recognize specific sequences within gene promoters, allowing them to regulate gene expression. In a speculative context, Erg Activators could interact with these DNA-binding domains, causing structural changes that either enhance or disrupt the proteins' ability to bind to DNA. This alteration in DNA-binding could, in turn, impact the transcriptional activity of target genes governed by Erg proteins, leading to downstream effects on various cellular pathways. However, it's essential to note that the concept of Erg Activators is purely theoretical, and their actual existence and functional mechanisms would require rigorous scientific investigation to ascertain their validity and within biological contexts.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
A protein kinase inhibitor that might influence signaling pathways involving ERG. | ||||||
Bicalutamide | 90357-06-5 | sc-202976 sc-202976A | 100 mg 500 mg | $42.00 $146.00 | 27 | |
An antiandrogen that could impact androgen signaling and ERG expression in prostate cancer. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
An HDAC inhibitor with potential effects on chromatin and gene expression, including ERG. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $231.00 $863.00 | 1 | |
A bromodomain inhibitor that could impact chromatin regulation and ERG expression. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
An oncogenic signaling inhibitor that might affect pathways related to ERG expression. | ||||||
MDV3100 | 915087-33-1 | sc-364354 sc-364354A | 5 mg 50 mg | $245.00 $1051.00 | 7 | |
An androgen receptor inhibitor researched for prostate cancer treatment that could impact ERG expression. | ||||||
Panobinostat | 404950-80-7 | sc-208148 | 10 mg | $200.00 | 9 | |
HDAC Inhibitors, such as vorinostat or panobinostat, which impact chromatin remodeling and gene expression. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $218.00 $322.00 $426.00 | 7 | |
A DNA methylation inhibitor that could affect epigenetic regulation of ERG. | ||||||